Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
Name:
36482128.pdf
Size:
720.0Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Locatelli, F.Zugmaier, G.
Rizzari, C.
Morris, J. D.
Gruhn, B.
Klingebiel, T.
Parasole, R.
Linderkamp, C.
Flotho, C.
Petit, A.
Micalizzi, C.
Zeng, Y.
Desai, R.
Kormany, W. N.
Eckert, C.
Möricke, A.
Sartor, M.
Hrusak, O.
Peters, C.
Saha, Vaskar
Vinti, L.
von Stackelberg, A.
Affiliation
IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy.Issue Date
2022
Metadata
Show full item recordAbstract
NoneCitation
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia. 2022 Dec 8. PubMed PMID: 36482128. Epub 2022/12/10. eng.Journal
LeukemiaDOI
10.1038/s41375-022-01770-3PubMed ID
36482128Additional Links
https://dx.doi.org/10.1038/s41375-022-01770-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41375-022-01770-3
Scopus Count
Collections
Related articles
- Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
- Authors: Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, Zeng Y, Pilankar D, Morris J, von Stackelberg A
- Issue date: 2022 Aug
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
- Authors: Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Möricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A
- Issue date: 2021 Mar 2
- High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
- Authors: Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M, Escoffre-Barbe M, Cluzeau T, Balsat M, Nguyen S, Pasquier F, Alexis M, Lheritier V, Pastoret C, Delabesse E, Clappier E, Dombret H, Boissel N
- Issue date: 2022 Sep 1
- Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
- Authors: Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC
- Issue date: 2011 Jun 20
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
- Authors: Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML
- Issue date: 2021 Mar 2